A carregar...
Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
BACKGROUND: Acute myeloid leukaemia (AML) is an aggressive blood cancer. In approximately 30% of the cases, driver mutations in the FLT3 gene are identified. FLT3 inhibitors are used in treatment of such patients together with cytotoxic drugs or (in refractory AML) as single agents. Unfortunately, r...
Na minha lista:
| Publicado no: | Cancer Cell Int |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8033742/ https://ncbi.nlm.nih.gov/pubmed/33832508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-021-01856-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|